Search
  • All Journals
Advanced Search
Search articles by Title, Author, Keywords, DOI
Submit Manuscript
0.7Impact Factor
Advanced Search
MAP  >  Gastrointestinal Tumors
2021 Volume 8
Article Contents
Next Previous
REVIEW ARTICLE   Open Access    

Cholangiocarcinoma: An Emerging Target for Molecular Therapy

  • a.

    Institute of Oncology, Hadassah Moscow, Moscow, Russian Federation

  • b.

    Hadassah Medical Center, Jerusalem, Israel

More Information
  • Background: Cholangiocarcinoma has been traditionally considered a tumor with poor prognosis. Until now, surgical treatment has been the only more or less effective approach.
    Summary: Over 10 years, chemotherapy with a combination of gemcitabine and cisplatin remains the standard first-line therapy for patients with locally advanced or metastatic cholangiocarcinoma, which leads to a median overall survival of 11.7 months. Several inhibitors of HER (ERBB), HGF/c-MET, Hedgehog, KRAS-BRAF-MEK-ERK, and PI3K/AKT/mTOR signaling pathways did not show their superiority to standard chemotherapy. The rise of hope is associated with the emergence of novel fibroblast growth factor receptors and isocitrate dehydrogenase inhibitors as well as immune checkpoint inhibitors.

  • Cite this article

    Ilya Tsimafeyeu, Mark Temper. 2021. Cholangiocarcinoma: An Emerging Target for Molecular Therapy. Gastrointestinal Tumors. 8:517258 doi: 10.1159/000517258
    Ilya Tsimafeyeu, Mark Temper. 2021. Cholangiocarcinoma: An Emerging Target for Molecular Therapy. Gastrointestinal Tumors. 8:517258 doi: 10.1159/000517258
    shu

Tables(1)

Download PDF

Article Metrics

Article views(753) PDF downloads(615)

Other Articles By Authors

Review Article   Open Access    

Cholangiocarcinoma: An Emerging Target for Molecular Therapy

  • a.

    Institute of Oncology, Hadassah Moscow, Moscow, Russian Federation

  • b.

    Hadassah Medical Center, Jerusalem, Israel

  • Received: 20 December 2020
  • Accepted: 18 May 2021
  • Published online: 21 July 2021
Gastrointestinal Tumors  8,  Article number: 10.1159/000517258  (2021)  |  Cite this article

Abstract: 

Background: Cholangiocarcinoma has been traditionally considered a tumor with poor prognosis. Until now, surgical treatment has been the only more or less effective approach.
Summary: Over 10 years, chemotherapy with a combination of gemcitabine and cisplatin remains the standard first-line therapy for patients with locally advanced or metastatic cholangiocarcinoma, which leads to a median overall survival of 11.7 months. Several inhibitors of HER (ERBB), HGF/c-MET, Hedgehog, KRAS-BRAF-MEK-ERK, and PI3K/AKT/mTOR signaling pathways did not show their superiority to standard chemotherapy. The rise of hope is associated with the emergence of novel fibroblast growth factor receptors and isocitrate dehydrogenase inhibitors as well as immune checkpoint inhibitors.

  • About this article
    Cite this article
    Ilya Tsimafeyeu, Mark Temper. 2021. Cholangiocarcinoma: An Emerging Target for Molecular Therapy. Gastrointestinal Tumors. 8:517258 doi: 10.1159/000517258
    Ilya Tsimafeyeu, Mark Temper. 2021. Cholangiocarcinoma: An Emerging Target for Molecular Therapy. Gastrointestinal Tumors. 8:517258 doi: 10.1159/000517258
    shu

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return